Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Afmedica Inc.

This article was originally published in Start Up

Executive Summary

It's not much of a stretch for companies to apply to other surgical markets the concepts that made drug-eluting stents such an overnight success. The overhealing response that characterizes in-stent restenosis is at the heart of many other processes that limit the long-term success of surgical interventions. In fact, Afmedica Inc. is building a drug plus device platform for vascular surgery around sirolimus, the very same drug that enabled Johnson & Johnson to be the first company to demonstrate that its drug-eluting stent prevents restenosis. Afmedica has built an IP estate around the use of the drug on the outside of vessels, where, in combination with non-inflammatory polymers, it might help reduce the failure of vascular access grafts for dialysis, prevent the closure of peripheral bypass grafts, and prevent surgical adhesions in abdominal surgery.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts